Kyverna Therapeutics Aktie News

Initial funding of $25 million from the first of four tranches  Facility strengthens Kyverna's financial flexibility, further supporting advancement of its late-stage indications in generalized myasthenia gravis (gMG) and stiff person syndrome (SPS), while also accelerating pre-launch activities Topline data readout of registrational Phase 2 SPS trial now expected in early 2026; narrowed from p...

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA)

EMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced it will host a conference call on Wednesday, October 29, 2025 at 8:00 AM ET to discuss the interim data from the KYSA-6 Phase 2 clinical trial evaluating KYV-101 in ...

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What's Happening: Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stockholders following a class action complaint that was filed against Kyverna on December 9, 2024 with a Class Period pursuant and/or traceable t...

KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS)

Oral presentation to include topline efficacy and safety data for 6 patients with up to  9 months of follow up ​

KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome